A PET/CT nomogram incorporating SUVmax and CT radiomics for preoperative nodal staging in non-small cell lung cancer

[1] Sakao Y(2011)The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe J Thorac Oncol 6 494-499

[2] Okumura S(2017)The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma J Thorac Cardiovasc Surg 153 702-709.e1

[3] Mingyon M(2018)Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy Lung Cancer 115 28-33

[4] Uehara H(2014)Analysis of predictive factors for postoperative survival for non small cell lung carcinoma patients with unexpected mediastinal lymph nodes metastasis Thorac Cardiovasc Surg 62 126-132

[5] Ishikawa Y(2018)Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 29 iv192-iv237

[6] Nakagawa K(2017)Surgically managed clinical stage IIIA-clinical N2 lung cancer in the Society of Thoracic Surgeons database Ann Thorac Surg 104 395-403

[7] Zhao Y(2016)Five-year survival among stage IIIA lung cancer patients receiving two different treatment modalities Med Sci Monit 22 2589-2594

[8] Li G(2000)Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann Thorac Surg 70 1826-1831

[9] Zheng D(2003)Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial J Clin Oncol 21 1752-1759

[10] Isaka M(2004)Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience Ann Oncol 15 1645-1653

[1] Sakao Y(2011)The impact of superior mediastinal lymph node metastases on prognosis in non-small cell lung cancer located in the right middle lobe J Thorac Oncol 6 494-499

[2] Okumura S(2017)The prognostic value of lymph node ratio and log odds of positive lymph nodes in patients with lung adenocarcinoma J Thorac Cardiovasc Surg 153 702-709.e1

[3] Mingyon M(2018)Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy Lung Cancer 115 28-33

[4] Uehara H(2014)Analysis of predictive factors for postoperative survival for non small cell lung carcinoma patients with unexpected mediastinal lymph nodes metastasis Thorac Cardiovasc Surg 62 126-132

[5] Ishikawa Y(2018)Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 29 iv192-iv237

[6] Nakagawa K(2017)Surgically managed clinical stage IIIA-clinical N2 lung cancer in the Society of Thoracic Surgeons database Ann Thorac Surg 104 395-403

[7] Zhao Y(2016)Five-year survival among stage IIIA lung cancer patients receiving two different treatment modalities Med Sci Monit 22 2589-2594

[8] Li G(2000)Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival Ann Thorac Surg 70 1826-1831

[9] Zheng D(2003)Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial J Clin Oncol 21 1752-1759

[10] Isaka M(2004)Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience Ann Oncol 15 1645-1653